For those that missed it in the H1, probably the most pertinent...

  1. 952 Posts.
    lightbulb Created with Sketch. 139
    For those that missed it in the H1, probably the most pertinent part:

    '...Strong news flow will continue in 2017 as we report on the clinical progress of CAVATAK as a potential new treatment in the fast-growing field of cancer immunotherapy.'

    Bring it on...

    Good buying opportunity atm, in my opinion...

    ML
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.